The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...
Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
Pfizer's marstacimab (Hympavzi), an IgG1 monoclonal antibody that helps promote clotting, remains on the market. The drug was ...
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
9h
GlobalData on MSNPfizer sets sights on Summit’s bispecific in combo with its ADCsSummit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Supporting Rapid Innovation through the PACT Initiative. Pfizer has focused on scientific innovation as a core value since it ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results